Christopher R Cogle

Summary

Affiliation: University of Florida
Country: USA

Publications

  1. pmc Aldehyde dehydrogenase activity as a functional marker for lung cancer
    Deniz Ucar
    Department of Medicine, University of Florida, Gainesville, FL, USA
    Chem Biol Interact 178:48-55. 2009
  2. ncbi request reprint Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes
    Christopher R Cogle
    Division of Hematology and Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Clin Adv Hematol Oncol 8:40-6. 2010
  3. pmc Angiogenesis in acute myeloid leukemia and opportunities for novel therapies
    Angelica Trujillo
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610 0278, USA
    J Oncol 2012:128608. 2012
  4. doi request reprint High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment
    Christopher R Cogle
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, United States Electronic address
    Leuk Res 38:71-5. 2014
  5. pmc The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells
    John M Ninos
    H, Lee Moffitt Cancer Center and Research Institute, Immunology Program, Department of Interdisciplinary Oncology, University of South Florida, SRB 2, 12902 Magnolia Drive, Tampa, FL 33612 9416, USA
    J Transl Med 4:9. 2006
  6. pmc Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries
    Christopher R Cogle
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610 0278, USA
    Blood 117:7121-5. 2011
  7. ncbi request reprint Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry
    Christopher R Cogle
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida, ARB R4 216B, Gainesville, FL 32610 0277, USA
    Stem Cells 25:1881-7. 2007
  8. doi request reprint Marrow cell therapies for cardiovascular diseases
    Christopher R Cogle
    Department of Medicine, Division of Hematology Oncology, Program in Stem Cell Biology and Regenerative Medicine, University of Florida College of Medicine, Gainesville, FL 32610 0278, USA
    Exp Hematol 36:687-94. 2008
  9. ncbi request reprint Typhlitis with concurrent appendicitis in a patient with chronic lymphocytic leukemia
    Christopher R Cogle
    University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
    Clin Adv Hematol Oncol 1:284-6; discussion 286. 2003
  10. pmc The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis
    Annet Kirabo
    Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, USA
    Am J Pathol 181:858-65. 2012

Collaborators

Detail Information

Publications42

  1. pmc Aldehyde dehydrogenase activity as a functional marker for lung cancer
    Deniz Ucar
    Department of Medicine, University of Florida, Gainesville, FL, USA
    Chem Biol Interact 178:48-55. 2009
    ..These observations and the known role of ALDH in drug resistance may have significant therapeutic implications in the treatment of lung cancer...
  2. ncbi request reprint Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes
    Christopher R Cogle
    Division of Hematology and Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Clin Adv Hematol Oncol 8:40-6. 2010
    ..Lineage analysis also found rapid donor chimerism of lymphocyte and granulocyte subsets. These data indicate the feasibility of pretransplant azanucleoside therapy in patients who subsequently receive an HCT...
  3. pmc Angiogenesis in acute myeloid leukemia and opportunities for novel therapies
    Angelica Trujillo
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610 0278, USA
    J Oncol 2012:128608. 2012
    ..By understanding how blood vessels can serve as a reservoir for refractory and relapsed AML, new diagnostics and promising treatment strategies can be developed...
  4. doi request reprint High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment
    Christopher R Cogle
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, United States Electronic address
    Leuk Res 38:71-5. 2014
    ..Only two-thirds of true MDS cases are captured in Florida using current case-finding mechanisms. Application of a keyword search strategy to identify cases among E-path reports is a feasible technique to improve MDS case ascertainment. ..
  5. pmc The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells
    John M Ninos
    H, Lee Moffitt Cancer Center and Research Institute, Immunology Program, Department of Interdisciplinary Oncology, University of South Florida, SRB 2, 12902 Magnolia Drive, Tampa, FL 33612 9416, USA
    J Transl Med 4:9. 2006
    ....
  6. pmc Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries
    Christopher R Cogle
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL 32610 0278, USA
    Blood 117:7121-5. 2011
    ..Based on the 2 + BCBM algorithm, the annual incidence of MDS is 75 per 100 000 persons 65 years or older-much higher than the 20 per 100 000 reported by SEER using the same sample...
  7. ncbi request reprint Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry
    Christopher R Cogle
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida, ARB R4 216B, Gainesville, FL 32610 0277, USA
    Stem Cells 25:1881-7. 2007
    ..Disclosure of Potential Conflicts of Interest is found at the end of this article...
  8. doi request reprint Marrow cell therapies for cardiovascular diseases
    Christopher R Cogle
    Department of Medicine, Division of Hematology Oncology, Program in Stem Cell Biology and Regenerative Medicine, University of Florida College of Medicine, Gainesville, FL 32610 0278, USA
    Exp Hematol 36:687-94. 2008
    ..The next generation of studies will aim to answers these questions and make way for cellular therapies that result in effective cardiac repair...
  9. ncbi request reprint Typhlitis with concurrent appendicitis in a patient with chronic lymphocytic leukemia
    Christopher R Cogle
    University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
    Clin Adv Hematol Oncol 1:284-6; discussion 286. 2003
  10. pmc The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis
    Annet Kirabo
    Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, USA
    Am J Pathol 181:858-65. 2012
    ..Collectively, these results indicate that G6 is efficacious in Jak2-V617F-mediated myelofibrosis, and given its bone marrow efficacy, it may alter the natural history of this disease...
  11. pmc Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells
    Nancy Y Villa
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
    Cytotherapy 18:465-80. 2016
    ..The aims of this study were to examine the impact of MYXV on normal hematopoietic stem and progenitor cells and define the optimal treatment conditions for ex vivo virotherapy...
  12. pmc Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus
    Eric Bartee
    Department of Molecular Genetics and Microbiology, University of Florida, College of Medicine, Gainesville, Florida, USA
    Biol Blood Marrow Transplant 18:1540-51. 2012
    ..We conclude that ex vivo myxoma treatment represents a safe and effective method to selectively eliminate myeloma cells from hematopoietic autografts before reinfusion...
  13. pmc The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow
    Annet Kirabo
    Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Neoplasia 13:1058-68. 2011
    ....
  14. pmc Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells
    Eric Bartee
    Department of Molecular Genetics and Microbiology, University of Florida, College of Medicine, Gainesville, Florida, United States of America
    PLoS ONE 7:e43298. 2012
    ....
  15. pmc Leukemia regression by vascular disruption and antiangiogenic therapy
    Gerard J Madlambayan
    Department of Medicine, University of Florida, Gainesville, USA
    Blood 116:1539-47. 2010
    ..Together, these data show that OXi4503 alone is capable of regressing AML by a multitargeted mechanism and that the addition of bevacizumab mitigates reactive angiogenesis...
  16. pmc Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger
    Gerard J Madlambayan
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida, Gainesville, Florida, USA
    Blood 114:4310-9. 2009
    ..The varied BM contribution seen in different model systems is suggestive of redundant mechanisms governing postnatal neovasculogenesis and provides an explanation for contradictory results observed in the field...
  17. ncbi request reprint Bone marrow transdifferentiation in brain after transplantation: a retrospective study
    Christopher R Cogle
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
    Lancet 363:1432-7. 2004
    ..We looked for evidence of clinically relevant marrow-derived restorative neurogenesis: long-term, multilineage, neural engraftment that is not the result of cell-fusion events...
  18. ncbi request reprint Developmental differences in megakaryocyte maturation are determined by the microenvironment
    William B Slayton
    University of Florida Department of Pediatrics, Gainesville, Florida 32610, USA
    Stem Cells 23:1400-8. 2005
    ..These differences may contribute to the delay in platelet engraftment that frequently complicates cord blood transplants...
  19. pmc Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro
    Gerard J Madlambayan
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
    Leuk Res 36:619-24. 2012
    ..Our results challenge the current dogma of oncolytic virotherapy and show that in vitro permissiveness to an oncolytic virus is not necessarily an accurate predictor of oncolytic potency in vivo...
  20. doi request reprint Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition
    Leylah Drusbosky
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
    Leuk Res 39:984-9. 2015
    ..Together, these results show direct cytotoxicity of RTKIs on AML cells and reversal of EC protection. Combining RTKIs with chemotherapy may serve as promising therapeutic strategy for patients with AML. ..
  21. pmc Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34
    Robert W Storms
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Box 3361, Durham, NC 27710, USA
    Blood 106:95-102. 2005
    ..The differential expression of ALDH may provide a means to explore normal and malignant processes associated with myeloid and lymphoid development...
  22. ncbi request reprint The hemangioblast: cradle to clinic
    Christopher R Cogle
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida Shands Cancer Center, Gainesville, Fla, USA
    Exp Hematol 32:885-90. 2004
    ..Finally, given that EPCs home to sites of new blood vessel growth, genetic engineering of harvested HSC or EPC offers the potential to deliver vasoregulatory factors directly to sites of neovascularization...
  23. ncbi request reprint Stem cell research
    Ronald C Sanders
    Divison of Pediatric Critical Care, Department of Pediatrics, University of Florida, Gainesville, 32610, USA
    Paediatr Respir Rev 7:135-40. 2006
    ..This review introduces the reader to the field of stem cell biology and its therapeutic potential. More importantly, the potential application of stem cell therapy in acute lung injury will be explored...
  24. doi request reprint A new model to predict remission status in AML patients based on day 14 bone marrow biopsy
    Maxim Norkin
    University of Florida, College of Medicine, Department of Medicine, Division of Hematology and Oncology, United States Electronic address
    Leuk Res 46:69-73. 2016
    ..88 vs. 0.80, P=0.002). Our new model provides better accuracy for predicting the likelihood of achieving remission and if validated in future studies may be useful for managing AML patients. ..
  25. doi request reprint Chemosensitizing AML cells by targeting bone marrow endothelial cells
    Raphael C Bosse
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL Electronic address
    Exp Hematol 44:363-377.e5. 2016
    ....
  26. pmc Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells
    Nancy Y Villa
    Division of Hematology and Oncology, Department of Medicine
    Blood 125:3778-88. 2015
    ..Given this dual capacity of reducing GVHD plus increasing the antineoplastic effectiveness of GVM, ex vivo virotherapy with MYXV may be a promising clinical adjunct to allo-HCT regimens. ..
  27. pmc Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus
    Masmudur M Rahman
    Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA
    Cytokine Growth Factor Rev 21:169-75. 2010
    ..We propose that a broader subset of patients with intractable hematologic malignancies who have failed standard therapy could become eligible for ABMT when the treatment schema is coupled with ex vivo oncolytic therapy...
  28. pmc The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance
    Jan S Moreb
    Division of Hematology Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, United States
    Chem Biol Interact 195:52-60. 2012
    ..In addition, other ALDH isoenzymes seem to play a major role in the biology and drug resistance of various malignant cells...
  29. pmc Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
    Nancy Y Villa
    Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL 32610, USA
    Viruses 8:85. 2016
    ..Recent advances using preclinical models with oncolytic viruses such as MYXV to ameliorate the deleterious consequences of GVHD, while maintaining or improving the anti-cancer benefits of GVC will be reviewed. ..
  30. doi request reprint Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease
    Manbok Kim
    Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA Electronic address
    Biochem Biophys Res Commun 462:283-7. 2015
    ..This provides support for developing myxoma virus as a potential oncolytic therapy for preventing EBV-associated LPDs following transplantation of bone marrow or solid organ allografts. ..
  31. ncbi request reprint Adult human hematopoietic cells provide functional hemangioblast activity
    Christopher R Cogle
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida Shands Cancer Center, Gainesville, FA 32610 0232, USA
    Blood 103:133-5. 2004
    ..Our results demonstrate human retinal neovascularization, thus revealing the functional hemangioblast activity of human hematopoietic cells...
  32. doi request reprint Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians
    Lamis K Eldjerou
    Departments of Pediatric Blood and Marrow Transplantation, Medicine and Biostatistics, University of Florida, Gainesville, Florida
    Transfusion 55:1766-71. 2015
    ..Given the importance of 25(OH)D in hematopoiesis, we examined the racial differences in UCB unit 25(OH)D content and its correlation with UCB cellular characteristics...
  33. pmc A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials
    Anita D Szady
    Division of Cardiovascular Medicine, University of Florida College of Medicine, 1600 S W Archer Rd, Gainesville, FL, USA
    Curr Atheroscler Rep 15:341. 2013
    ..Uniform criteria need to be developed to better define clinical outcomes of interest. Furthermore, a refocus from heart failure outcomes to ischemia-related outcomes seems appropriate...
  34. doi request reprint Characteristics of thawed autologous umbilical cord blood
    Emma H Rosenau
    Department of Medicine, University of Florida, and Shands Hospital, University of Florida, Gainesville, Florida, USA
    Transfusion 52:2234-42. 2012
    ..Increasingly, private AutoUCB banking is performed for therapies unavailable today. A Phase I trial using AutoUCB treatment for early pediatric Type 1 diabetes afforded us an opportunity to analyze characteristics of AutoUCBs...
  35. pmc Oncolytic virotherapy for hematological malignancies
    Swarna Bais
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, ARB R4 202, P O Box 100278, Gainesville, FL 32610 0278, USA
    Adv Virol 2012:186512. 2012
    ..This paper details experimental progress with reovirus, myxoma virus, measles virus, vesicular stomatitis virus, coxsackievirus, and vaccinia virus as well as requirements for translation of these results to the clinic...
  36. ncbi request reprint An overview of stem cell research and regulatory issues
    Christopher R Cogle
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida Shands Cancer Center, Gainesville 32610, USA
    Mayo Clin Proc 78:993-1003. 2003
    ..This article was written to inform medical scientists and practicing clinicians across the spectrum of medical education about the research and regulatory issues affecting the future of stem cell therapy...
  37. doi request reprint Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience
    Lakshmikanth Katragadda
    Department of Medicine, University of Florida, Gainesville, FL, USA
    Clin Transplant 30:894-900. 2016
    ..024), but not OS (P=.104). In conclusion, MM patients who received MEL140 had similar long-term outcomes to MEL200 patients despite their older age and co-morbidities. ..
  38. doi request reprint Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients
    Leylah Drusbosky
    Department of Hematology Oncology 1600 SW Archer Rd PO box 100278, Gainesville, FL 32610, USA
    Leuk Res 52:1-7. 2016
    ..We demonstrate that a computational technology is able to map the complexity of the MDS mutanome to simulate and predict drug response. This tool can improve understanding of MDS biology and mechanisms of drug sensitivity and resistance...
  39. doi request reprint Acute myeloid leukemia in the vascular niche
    Christopher R Cogle
    Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA Electronic address
    Cancer Lett 380:552-60. 2016
    ....
  40. pmc Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells
    Seungbum Kim
    From the Departments of Physiology and Functional Genomics S K, M Z, M K R, Pharmacology and Therapeutics J K H, D L, Molecular Genetics and Microbiology E W S, and Medicine C R C, College of Medicine, University of Florida, Gainesville
    Hypertension 67:574-84. 2016
    ..These observations highlight the important regulatory roles of Ang II on HSC proliferation, differentiation, and engraftment. ..
  41. pmc Mapping hematopoiesis in a fully regenerative vertebrate: the axolotl
    David Lopez
    Program in Stem Cell Biology and Regenerative Medicine, University of Florida, Gainesville, FL Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL
    Blood 124:1232-41. 2014
    ..Organ segregation, made possible by embryonic microsurgeries wherein halves of 2 differently colored embryos were joined, indicate that the spleen is the definitive site of adult hematopoiesis. ..
  42. pmc The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo
    Annet Kirabo
    Department of Physiology and Functional Genomics, University of Florida College of Medicine, Gainesville, Florida 32610, USA
    J Biol Chem 286:4280-91. 2011
    ..Collectively, these data demonstrate that the stilbenoid compound, G6, suppresses Jak2-V617F-mediated aberrant cell growth. As such, G6 may be a potential therapeutic lead candidate against Jak2-mediated, human disease...